{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ffc1fe6b303132625aa8d15/6a7ae73395b3ceeb6d61425d?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Obe-cel for relapsed/​refractory B-ALL: The FELIX study ","description":"<p>During the ALL Hub Steering Committee meeting in April 2026, Daniel DeAngelo led a discussion on the latest findings from the phase Ib/II FELIX trial (NCT04404660) investigating obecabtagene autoleucel (obe-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). The discussion featured contributions from Ibrahim Aldoss, José María Ribera, André Baruchel, Wendy Stock, and Nicolas Boissel.&nbsp;&nbsp;</p><p><br></p><p><em>This educational resource is independently supported by Autolus. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.</em></p>","author_name":"Scientific Education Support"}